Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Kaplan-Meier method

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    187 result(s) found for: Kaplan-Meier method. Displaying page 4 of 10.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-000452-18 Sponsor Protocol Number: ETB115J2411 Start Date*: 2018-09-26
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II, open-label, prospective, single-arm, study to assess ability of eltrombopag to induce sustained remission in subjects with ITP who are refractory or relapsed after first-line steroids (...
    Medical condition: immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10050245 Autoimmune thrombocytopenia LLT
    22.1 100000004851 10036735 Primary thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GR (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002944-10 Sponsor Protocol Number: c16174 Start Date*: 2019-02-27
    Sponsor Name:Memorial Sloan Kettering Cancer Center
    Full Title: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Medical condition: Patients with histological or cytological proof of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003494-25 Sponsor Protocol Number: CAEB071A2203 Start Date*: 2006-08-30
    Sponsor Name:Novartis Pharma Services AG
    Full Title: 12-month open label, randomized, multicenter study evaluating efficacy, safety and tolerability of oral AEB071 plus tacrolimus (converted to myfortic after 3 months), vs. myfortic plus tacrolimus i...
    Medical condition: First evaluation of the efficacy and safety of AEB071 in its target indication: prevention of rejection in solid organ tranplantation. The study population will consist of a representative group of...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003184-62 Sponsor Protocol Number: J1369 Start Date*: 2014-04-23
    Sponsor Name:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Full Title: A phase I study of SGI-110 combined with irinotecan followed by a randomized phase II study of SGI-110 combined with irinotecan versus regorafenib in previously treated metastatic colorectal cancer...
    Medical condition: Previously treated metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010030 Colorectal cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003497-14 Sponsor Protocol Number: BLU-285-1303 Start Date*: 2018-04-23
    Sponsor Name:Blueprint Medicines Corporation
    Full Title: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
    Medical condition: Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051066 Gastrointestinal stromal tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) SE (Completed) HU (Completed) DE (Completed) NL (Completed) AT (Completed) ES (Completed) BE (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004084-49 Sponsor Protocol Number: TAS-120-202 Start Date*: 2020-06-22
    Sponsor Name:Taiho Oncology Inc.
    Full Title: A PHASE 2 STUDY OF FUTIBATINIB IN PATIENTS WITH SPECIFIC FGFR ABERRATIONS
    Medical condition: Fibroblast growth factor receptor (FGFR) aberrations
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) BE (Completed) PT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004997-41 Sponsor Protocol Number: H7T-MC-TACW Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company
    Full Title: Effectiveness of Prasugrel versus Clopidogrel in Subjects with High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention with Implantation of Drug-Eluting Stent
    Medical condition: Reduction of composite cardio-vascular end-point in patients who have successfully undergone elective percutaneous coronary intervention with placement of at least one drug-eluting stent.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003993-24 Sponsor Protocol Number: CA186006 Start Date*: 2008-05-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects with Previously Treated Unresectable Stage III or Stage IV Melanoma. Revised Protocol 0...
    Medical condition: MELANOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025670 Malignant melanoma stage III LLT
    9.1 10025671 Malignant melanoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) IT (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004879-46 Sponsor Protocol Number: RG_16-123 Start Date*: 2017-06-15
    Sponsor Name:University of Birmingham
    Full Title: AVAIL-T: A Phase 2a trial of Avelumab, an anti-PDL1 antibody, in relapsed and refractory peripheral T-cell lymphoma (PTCL)
    Medical condition: Relapsed and refractory T-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001413 Adult T-cell lymphoma/leukaemia PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-019033-98 Sponsor Protocol Number: BMS-TUE-01 Start Date*: 2011-10-27
    Sponsor Name:University Clinical Center of Tuebingen
    Full Title: A phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma
    Medical condition: Stage IV Melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002512-49 Sponsor Protocol Number: PRS-343-PCS_09_20 Start Date*: 2022-06-13
    Sponsor Name:Pieris Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multi-Center, Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Aden...
    Medical condition: HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002231-24 Sponsor Protocol Number: PROICM2018-01NEX Start Date*: 2018-08-06
    Sponsor Name:Institut régional du Cancer de Montpellier
    Full Title: A randomized phase III trial assessing a regorafenib-irinotecan combination (REGIRI) versus regorafenib alone in metastatic colorectal cancer patients after failure of standard therapies, according...
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003022-92 Sponsor Protocol Number: 9785-CL-0403 Start Date*: 2014-04-29
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutam...
    Medical condition: Medical condition: metastatic castration-resistant prostate cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) DE (Completed) HU (Completed) GB (Completed) BE (Completed) FI (Completed) IT (Completed) CZ (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000454-22 Sponsor Protocol Number: CCR4825 Start Date*: 2019-02-01
    Sponsor Name:The Royal Marsden NHS Foundation Trust
    Full Title: A translational phase II study of single agent Olaparib in the treatment of advanced oesophagogastric cancer
    Medical condition: Advanced Oesophago-gastric cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-004831-30 Sponsor Protocol Number: UC-0101/1104 Start Date*: 2012-09-21
    Sponsor Name:UNICANCER
    Full Title: Safety and efficacy of radiotherapy combined with a 6-month LH-RH agonist and abiraterone hormone therapy treatment in biochemically-relapsing prostate cancer following surgery.
    Medical condition: Biochemically-relapsing prostate adenocarcinoma following radical prostatectomy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001186 Adenocarcinoma of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001804-39 Sponsor Protocol Number: GLLC-EARLY Start Date*: 2019-09-24
    Sponsor Name:Fundación PETHEMA
    Full Title: Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression
    Medical condition: Early Stage CLL With High Risk of Early Disease Progression
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002345-39 Sponsor Protocol Number: Göteborg University Start Date*: 2006-02-16
    Sponsor Name:NOPHO NHL-group
    Full Title: B-NHL BFM 04
    Medical condition: B-cell lymphoma or B-ALL in children up to 18 years of age
    Disease:
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000227-24 Sponsor Protocol Number: RG_13-320 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Birmingham
    Full Title: A Study of Thiotepa, Ifosphamide, Etoposide and Rituximab for the treatment of relapsed or refractory primary central nervous system lymphoma
    Medical condition: Relapsed or refractory primary central neurvous system lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007953 Central nervous system lymphoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-003993-16 Sponsor Protocol Number: IM-T-hPAM4-02 Start Date*: 2009-04-03
    Sponsor Name:Immunomedics, Inc.
    Full Title: A Phase Ib/II Study of Fractionated 90-Y-hPAM4 Plus Gemcitabine in Patients with Previously Untreated Advanced Pancreatic Cancer
    Medical condition: This is a phase Ib, open-label, dose exploration study of 90-Y-hPAM4 administered as one or more treatment cycles of fractionated radioimmunotherapy in combination with radiosensitizing gemcitabine...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033605 Pancreatic cancer metastatic LLT
    9.1 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005396-34 Sponsor Protocol Number: RG_10-040 Start Date*: 2004-09-22
    Sponsor Name:University of Birmingham
    Full Title: Treatment Protocol for T-Cell and B-Precursor Cell Lymphoblastic Lymphoma of the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL)
    Medical condition: lymphoblastic lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065923 Lymphoblastic lymphoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 16 05:23:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA